APA (7th ed.) Citation

Kocaaslan, E., Güren, A. K., Akagündüz, F., Demirel, A., Tunç, M. A., Paçacı, B., . . . Bayoğlu, I. V. (2026). Prognostic Value of 18 F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine, 15(2), 798. https://doi.org/10.3390/jcm15020798

Chicago Style (17th ed.) Citation

Kocaaslan, Erkam, et al. "Prognostic Value of 18 F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab." Journal of Clinical Medicine 15, no. 2 (2026): 798. https://doi.org/10.3390/jcm15020798.

MLA (9th ed.) Citation

Kocaaslan, Erkam, et al. "Prognostic Value of 18 F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab." Journal of Clinical Medicine, vol. 15, no. 2, 2026, p. 798, https://doi.org/10.3390/jcm15020798.